glp-1 agonists cardiovascular diseases and mortality outcomes with receptor vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Frontiers | The benefits of
Description
GLP-1 is released by intestinal L cells when nutrients are consumed
Meta-analyses have confirmed the benefit of GLP-1 RAs as a class in both secondary and primary prevention of cardiovascular disease, and in reduction of adverse kidney outcomes in people with T2D (Kristiensen et al, 2019
Ohtake N, Saito M, Eto M, Seki K
Kalra S, Bahendeka S, Sahay R, et al
Alternatively, others like dulaglutide (Trulicity) are administered once a week
